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Pulmonary arterial hypertension (PAH) is associated with symptoms of dyspnea and fatigue, which contribute to exercise limi-
tation. The origins and signiﬁcance of dyspnea and fatigue in PAH are not completely understood. This has created uncertainly
among healthcare professionals regarding acceptable levels of these symptoms, on exertion, for patients with PAH. Dysfunction of
the right ventricle (RV) contributes to functional limitation and mortality in PAH; however, the role of the RV in eliciting dyspnea
and fatigue has not been thoroughly examined. This paper explores the contribution of the RV and systemic and peripheral
abnormalities to exercise limitation and symptoms in PAH. Further, it explores the relationship between exercise abnormalities
and symptoms, the utility of the cardiopulmonary exercise test in identifying RV dysfunction, and oﬀers suggestions for further
research.
1.Introduction
Pulmonary arterial hypertension is a condition deﬁned by
primaryabnormalitiesintheprecapillarypulmonaryarteries
and arterioles. It forms group 1 of the World Health Orga-
nization classiﬁcation of pulmonary hypertension (PH) [1].
This classiﬁcation system identiﬁes PAH as a speciﬁc entity,
with a characteristic pathophysiology, clinical presentation,
and response to therapy that helps separate it from other
forms of pulmonary hypertension.
The most commonly reported symptoms on presenta-
tion in individuals with PAH are dyspnea and fatigue. These
symptoms limit physical function, and, by the time of diag-
nosis, most individuals have marked functional limitation
and are in the New York Heart Association (NYHA) Func-
tional class III or IV [2]. The New York Heart Association
reﬂects disease severity and prognosis, and disease pro-
gression is associated with worsening symptoms and func-
tional capacity [1]. Recent development of pharmaceutical
therapies, which address the speciﬁc pulmonary vascular
abnormalities associated with PAH, has resulted in improved
hemodynamics,exercisecapacity[3,4],andprognosis[3]for
individuals with PAH. However, despite therapy, many indi-
viduals continue to have exertional symptoms, functional
limitation and impaired quality of life (QoL) [5].
Exercise training has well-established safety and eﬃcacy
for improving exercise capacity and QoL in chronic obstruc-
tive pulmonary disease (COPD) [6] and left heart failure
(LHF) [7]. Although, historically, physical activity and exer-
cise training were discouraged for individuals with PAH,2 Pulmonary Medicine
interest has recently developed in the role of exercise training
for individuals with PAH who have persistent functional
impairments,despitepharmaceuticaltherapy.Evidencefrom
several small studies suggests that well-designed exercise
training programs improve exercise capacity and QoL,
without major adverse events or clinical deterioration, in
individuals who are stable on PAH-speciﬁc pharmaceutical
therapy [8–12]. These studies reporting exercise training
have utilized moderate-intensity exercise.
In a study using a monocrotaline rat model of PAH,
which investigated moderate intensity aerobic training [13],
RV myocardial capillary density increased and exercise
capacity improved following exercise training in rats with
stable PAH. However, in rats in which progressive PAH had
been induced with a higher dose of monocrotaline, signs
of RV inﬂammation and poorer survival occurred following
exercise training, in comparison with sedentary rats and rats
with stable PAH which had undergone exercise training [13].
The paucity of literature reporting exercise training in
PAH has resulted in uncertainty among healthcare profes-
sionals regarding appropriate levels of physical exertion for
individuals with PAH, and which patients are suitable for
exercise rehabilitation [14]. Furthermore, there is little in the
literature regarding the causes and signiﬁcance of dyspnea
and fatigue associated with PAH. Consequently, healthcare
professionals demonstrate inconsistency with respect to
recommendations for appropriate levels of dyspnea and
fatigue during the performance of daily activities in this
population [14]. In light of the current interest in exercise
traininginPAH,itistimelythatconsiderationbegiventothe
hemodynamic consequences and origins and signiﬁcance of
the symptoms associated with physical exertion in PAH. This
paper discusses the literature around exercise physiology in
PAH, the likely impact of RV dysfunction and systemic and
peripheral abnormalities on dyspnea, fatigue, and exercise
limitation.
2. CentralHemodynamics in PAH
A fundamental endothelial abnormality is thought to play a
key role in the pathogenesis and functional abnormali-
ties associated with PAH. Imbalance in the production
of pulmonary vasodilators and vasoconstrictors, abnormal
proliferation of cells in the walls of the small pulmonary
arteries and arterioles, and intra-luminal thrombus result in
a marked reduction in the vasodilatory capacity, distensibil-
ity, and patency of the pulmonary circulation [15, 16]. The
clinical outcome is a rise in pulmonary vascular resistance
(PVR), pulmonary artery pressure (PAP), and RV afterload
[17].
Inanormalheart,theRVresponsetoasustainedincrease
in afterload is adaptive myocardial hypertrophy. In PAH,
with progressive vascular changes leading to an unrelenting
increase in PVR, there is a transition from RV wall hyper-
trophy to RV dilatation [18]. The capacity for hypertrophic
adaptation varies among individuals [19], and it has been
proposed that the development of right heart failure in
PAH is not only related to elevated RV afterload but also
to intrinsic abnormalities of the RV wall [20]a n dm a y
be related to myocardial inﬂammation [13]. Altered gene
expression is thought to contribute to the development of
RV dysfunction in some individuals [21]. In scleroderma,
RV function can be further compromised by intrinsic
abnormalities of the myocardium, which may be secondary
to chronic inﬂammation [22]. However, the predominant
cause of RV failure in PAH is believed to be RV ischemia due
to imbalance between oxygen supply and demand associated
with hypertrophy, increased RV workload and increased
metabolic demand [23], without a concomitant increase in
capillarization [13, 18, 20, 24] and blood supply [25].
Initially, dilatation of the right atrium and RV in PAH
results in a compensatory increase in preload and mainte-
n a n c eo fs t r o k ev o l u m e( S V ) ,b u ta sc o n t r a c t i l ed y s f u n c t i o n
worsens,diastolicdysfunctiondevelops, ﬁllingpressuresrise,
a n dR Vo u t p u tf a l l s[ 26]. The resultant decrease in left ven-
tricular (LV) preload [27] and pressure-related movement of
the interventricular septum to the left and LV compression
[28], lead to a fall in LV output and systemic oxygen delivery
[29, 30].
3. ExerciseAbnormalities
Impairment in the distensibility and vasodilatory capacity
and reduction in the size of the pulmonary vascular bed
mean that an increase in pulmonary blood ﬂow with exercise
can only be achieved with a marked rise in PAP [31]a n dR V
afterload [17]. Reduced RV contractility results in a reduced
capacity for SV to augment cardiac output (CO) during
exercise [30]. In addition to reduced SV, PAH is associated
with chronotropic impairment [32], demonstrated by a
failure to achieve a normal maximum heart rate at peak
exercise[32–35].ChronotropicimpairmentinPAHisrelated
to downregulation of RV myocardial beta-adrenoreceptor
activity [36] and reﬂects disease severity [32, 37]. The com-
binedfailureofSVandheartratetoincreasenormallyduring
exercise results in an attenuated rise in CO and systemic
blood pressure [38]. Prognosis in PAH is known to be closely
associated with RV function [26] and the systemic blood
pressure response during exercise [38]. Ultimately the RV
fails to function adequately at rest, and, in the majority of
cases, death occurs from RV failure [21].
4. The Inﬂuenceof Right VentricularFunction
on ExerciseCapacityand Symptoms
Thereisincreasingawarenessthattheprimarycauseofsymp-
toms [39], functional impairment and mortality in PAH is
RV dysfunction [23]. Along with being strongly associated
withsurvival[40,41],rightatrialpressurehasbeenidentiﬁed
as the hemodynamic measure that has the strongest (neg-
ative) correlation with exercise capacity in individuals with
PAH [42]. Furthermore, indicators of RV function, SV and
chronotropic response, are strong and independent factors
in determining the six-minute walk distance (6MWD) [32].
Improvements in 6MWD are positively related to changes in
SV, and chronotropic response [32] and cardiac index [17]Pulmonary Medicine 3
and negatively related to changes in PVR and the Borg scale
rating of dyspnea following PAH-speciﬁc therapy [32].
Treatments that improve hemodynamics by unloading the
RV, and/or improving RVcontractility, have also been shown
to improve NYHA functional class [17].
Further insights into the role of the RV in the generation
of symptoms and reduction in exercise capacity can be
gained from studies in patients with left heart failure (LHF).
Pulmonary hypertension, due to elevated pulmonary venous
pressure, is commonly associated with LHF [43, 44]. While
there is a poor correlation between exercise capacity and left
ventricular function in LHF [45], RV function inﬂuences
both exercise capacity and prognosis in this condition
[46]. Resting PAP and PVR correlate inversely, and right
ventricular ejection fraction correlates positively with peak
oxygen consumption (VO2)[ 47, 48] .Ah i g hp r e v a l e n c eo f
PH has also been reported in chronic obstructive pulmonary
disease (COPD) [49, 50] and pulmonary ﬁbrosis [51, 52]. In
these conditions, and in LHF, exercise capacity is lower and
levels of dyspnea and fatigue are greater in individuals with
pulmonary hypertension than those without [50, 52–55].
Recently, a study of individuals with normal hemody-
namics at rest, but a persistent reduction in exercise capacity
following successful pulmonary endarterectomy for chronic
thromboembolic disease, was undertaken to investigate the
cause of persistent exertional dyspnea and functional limi-
tation [56]. This study identiﬁed elevated PVR and reduced
pulmonary arterial compliance during exercise, and reduced
exercise capacity in these individuals, in comparison with
a control group. The combination of PVR and pulmonary
arterial compliance reﬂects the hydraulic load imposed by
the pulmonary circulation on the RV, and the ﬁndings of
this study support the suggestion that elevated RV afterload
negatively impacts on exercise capacity and contributes to
exertional dyspnea [56].
The RV most likely contributes to the sensation of
dyspnea via mechanoreceptors situated in the right atrium
and RV. These receptors relay details of right atrial and RV
pressure and volume and the amount of work performed by
the RV [57, 58], via aﬀerent sympathetic pathways, to the
central nervous system. In PAH an increase in sympathetic
activity [59] appears directly related to the degree of
elevation of right atrial [60]o rR Vs y s t o l i cp r e s s u r e[ 61]. In
animal models, sympathetic pathways have been implicated
in mediating the association between RV work load and
ventilatory response [62], with increased RV pressure, and
stimulationofmechanoreceptorsintherightatrium,directly
resulting in increased ventilation [62, 63].
5. Other Abnormalities That
Contribute to Reduced Exercise Capacity
andSymptoms inPAH
5.1. Gas Exchange and Hypoxemia. Reduced diﬀusing capac-
ity for carbon monoxide (DLCO) is a common ﬁnd-
ing in PAH [41, 64–67]. Reduced DLCO appears to be
related primarily to impaired pulmonary membrane dif-
fusing capacity and, to a lesser extent, reduced pulmonary
capillary blood volume [66, 67]. Reduced DLCO has been
shown to correlate with reduced exercise capacity and a
higher functional class in PAH [68], likely reﬂecting disease
severity. However, reduced DLCO also indicates a limited
capacity for pulmonary gas exchange. In individuals with
moderate to severe PAH, without a patent foramen ovale, a
progressive fall in oxygen saturation occurs during exercise
[35, 38]. It has been proposed that this results from reduced
venous oxygen saturation secondary to reduced CO and
tissue oxygen delivery [69]. At rest, mixed venous oxygen
saturation has been shown to correlate with arterial oxygen
tension (PaO2)[ 70, 71] .H o w e v e r ,r e d u c e do x y g e nu p t a k ei n
the lung secondary to rapid red cell transit time, diﬀusion
impairment [66], and ventilation/perfusion mismatch [70,
72] also contributes to hypoxemia.
Hypoxemia stimulates ventilation through central chem-
oreceptors in the medulla and peripheral chemoreceptors in
the carotid and aortic bodies. However, central chemore-
ceptors are generally only stimulated when PaO2 is close to,
or below, 50mmHg [73]. There are conﬂicting data in the
literature regarding a correlation between the ventilatory
response(representedbytheventilatoryequivalentforcarbon
dioxide [ ˙ VE/ ˙ VCO2]) during exercise and arterial oxygen
tension (PaO2), in individuals with PAH. Although early
studies identiﬁed no correlation between ˙ VE/ ˙ VCO2 and
PaO2 [74, 75], a recent study identiﬁed a correlation at rest
and at the anaerobic threshold [71]. Both elevated ˙ VE/ ˙ VCO2
and reduced PaO2 reﬂect disease severity in PAH [38, 71],
and a direct link between the ventilatory response and
hypoxemia in this condition has not been established. In
LHF, hyperventilation during exercise occurs in the absence
of hypoxemia [76]. Except in the presence of a patent fora-
men ovale or severe disease, the levels of hypoxemia in
PAH are insuﬃcient to stimulate hypoxia sensitive central
chemoreceptors, and it is, therefore, unlikely that hypoxemia
makes a signiﬁcant contribution to hyperventilation in the
majority of individuals with PAH.
Hypoxemia may, however, contribute to a sensation of
dyspnea by predisposing the respiratory muscles to fatigue.
In healthy individuals undergoing prolonged exercise,
fatigue-induced changes in the contractile properties of the
respiratory muscles contribute to a sensation of dyspnea
through imbalance in inspiratory muscle eﬀort relative to
capacity [77]. The dyspnea associated with central nervous
system’s perception of inspiratory motor output, relative to
capacity, is also inﬂuenced by a reduction in respiratory
muscle strength [78]. Respiratory muscle weakness has been
demonstrated in PAH [79, 80], and there is evidence of
atrophy of type I and type II muscle ﬁbres in the diaphragm
of humans with PAH [81]. In the presence of hypoxemia,
alongwithelevatedventilation, respiratorymuscleweakness,
and reduced CO, the respiratory muscles are predisposed to
fatigue, which may contribute to the sensation of dyspnea
during exercise in PAH.
5.2. Chemoreceptor Activation. It is likely that reduced oxy-
gendeliverycontributestoincreasedventilationanddyspnea
in PAH via activation of skeletal muscle chemoreceptors.4 Pulmonary Medicine
Reduced muscle cell pH associated with anaerobic metab-
olism stimulates intra- and extra-cellular chemoreceptors
within the muscle and, via the ergoreﬂex, results in increased
ventilation [82, 83]. In LHF, in the longer term, reduced
CO during exercise, and chronic muscle acidosis [84]r e s u l t
in increased ergoreﬂex sensitivity [85–87] and increased
ventilation and dyspnea [45]. It has been proposed that
peripheral chemoreceptor stimulation [59] and possibly
increased ergoreﬂex sensitivity also contribute to increased
ventilation and dyspnea in PAH, although there are no data
to conﬁrm this possibility, to date.
5.3.SystemicEndothelialDysfunction. Tissueoxygendelivery
andaerobicmetabolismdependuponadequatesystemicvas-
cular function, along with CO and arterial oxygen content.
Duetotheinﬂuenceofthesystemicendotheliumonvascular
tone and blood ﬂow, endothelial dysfunction is believed to
negatively impact on oxygen delivery to the periphery in
LHF [88–90]. Evidence of systemic endothelial dysfunction
in PAH [91]suggeststhatreducedperipheralblood ﬂowmay
also be a source of impaired oxygen delivery, muscle acidosis,
and elevated ventilation, during exercise, in PAH.
5.4. Skeletal Muscle Myopathy. Recent studies have identiﬁed
muscle ﬁbre changes and skeletal muscle weakness in indi-
viduals with PAH [92, 93]. The muscle ﬁbre changes include
a lower portion of type I muscle ﬁbres and an enzyme
proﬁle compatible with a relatively higher potential for
anaerobic than aerobic energy metabolism [93]. The cause
of skeletal muscle dysfunction in PAH is uncertain, although
it is likely related to chronic muscle acidosis, increased
sympathetic activity [59, 61], systemic inﬂammation [94,
95], and neurohormonal changes [18], similar to the causes
of skeletal muscle dysfunction in LHF [96]. Similarities in
muscle dysfunction in LHF, COPD, and PAH also suggest
that skeletal muscle atrophy and alterations in muscle mor-
phology in PAH may contribute to an elevated ventilatory
drive, and dyspnea, as described in LHF and COPD [45, 97,
98]. The improvement in muscle morphology and exercise
capacity following exercise training in PAH [10, 11] suggests
that deconditioning also contributes to exercise limitation in
PAH.
6. Ventilatory Response in PAH
Characteristic ventilatory abnormalities have been well
deﬁned in PAH. Hyperventilation at rest and on exercise,
identiﬁed by an elevated ˙ VE/ ˙ VCO2 and reduced arterial
carbon dioxide tension (PaCO2), is a well-recognised feature
of PAH [35, 38, 74, 75, 99]. The elevated ˙ VE/ ˙ VCO2 in PAH
describes a dissociation between carbon dioxide production,
PaCO2, and minute ventilation. The altered relationship
between ˙ VE/ ˙ VCO2,P a C O 2, and arterial pH described in
PAH [74] suggests that elevated ˙ VE/ ˙ VCO2 during sub-
maximal exercise in PAH is not mediated by changes in
arterial blood gases. Initial reports of an elevated ˙ VE/ ˙ VCO2
suggested that increased ventilation in PAH was due to
ventilatory ineﬃciency caused by obstruction of the small
pulmonary vessels and subsequent ventilation/perfusion
inequalities [74, 75, 99]. However, this is unlikely to be the
predominant mechanism, as ventilation/perfusion studies in
PAH do not demonstrate marked ventilation/perfusion mis-
match, at rest or on exercise [70, 100]. Furthermore, in PAH
it is well established that PaCO2 i sr e d u c e da tr e s ta n do n
exercise [40, 71]. If ventilatory ineﬃciency was the sole cause
of an elevated ˙ VE/ ˙ VCO2,P a C O 2 would be normal. An
increased ventilatory drive, rather than ventilatory ineﬃ-
ciency, is likely to be reﬂected in an elevated ˙ VE/ ˙ VCO2 in
the presence of a reduced PaCO2,a ss e e ni nP A H .T h i s
hypothesis warrants further investigation.
There is evidence that the elevated ventilatory response
associated with PAH is related to central haemodynamic
abnormalities. The ˙ VE/ ˙ VCO2 at rest has been shown to
correlate with PVR, and both ˙ VE/ ˙ VCO2 and PVR decrease
in response to treatment with an intravenous prostacyclin
analogue [101]. The ˙ VE/ ˙ VCO2 correlates with PAP [75].
Arterial carbon dioxide tension has been shown to correlate
with cardiac index and changes in cardiac index associated
with disease progression and increasing PVR are reﬂected by
changes in both ˙ VE/ ˙ VCO2 and PaCO2 [71]. The ˙ VE/ ˙ VCO2
reﬂects disease severity and has been shown to correlate with
NYHA functional class [35]. Furthermore, the ˙ VE/ ˙ VCO2
[38], and PaCO2 are both prognostic markers in PAH [71].
In LHF, RV workload, indirectly determined by mea-
surement of RV oxidative metabolism [102, 103]a n dP V R
[53, 104], correlates with ˙ VE/ ˙ VCO2. Furthermore, in this
condition, a signiﬁcant negative relationship exists between
RV ejection fraction and ˙ VE/ ˙ VCO2 [104]. Changes in exer-
cise PVR following treatment with the phosphodiesterase
inhibitor, sildenaﬁl, also correlate signiﬁcantly with changes
in ˙ VE/ ˙ VCO2 [105] although there is no correlation between
left ventricular function at peak exercise and ˙ VE/ ˙ VCO2
[104]. Furthermore, the increase in ˙ VE/ ˙ VCO2 reﬂects the
degree in elevation of PAP [106] supporting a relationship
between RV work, ventilatory response, and symptoms in
this condition.
A distinct pattern of change in end-tidal carbon dioxide
tension (PetCO2) during exercise is evident in individuals
with PAH. In severe PAH, PetCO2 i sl o wa tr e s ta n df a l l s
progressively throughout an incremental exercise test [31,
107, 108], most likely reﬂecting a low and falling PaCO2 at
rest and on exercise, respectively. During recovery PetCO2
rises, reﬂecting slowed gas exchange kinetics and delayed
recovery [31]. In moderate PAH the rise in PetCO2 from
rest to the anaerobic threshold (AT) is minimal, or absent,
and in mild PAH the rise in PetCO2 from rest to the AT is
attenuated [108]. This particular pattern of PetCO2 response
distinguishes PAH from other conditions [107].
7. Evidenceof RV Dysfunctionon
a Cardiopulmonary ExerciseTest (CPET)
inIndividualswith PAH
In PAH, the incremental CPET consistently identiﬁes
r e d u c e dp e a ko x y g e nc o n s u m p t i o na n dr e d u c e dV O 2 at
the AT [31, 35, 38, 99, 109] ,r e d u c e do x y g e n( O 2) pulsePulmonary Medicine 5
[35, 38, 110], and slowed VO2 kinetics [31]. The relationship
between CO and oxygen consumption is very strong in
healthy individuals, such that VO2 is considered a surrogate
of CO and VO2/HR, or O2 pulse has been used as a surrogate
of SV [111]. Reduced VO2 at peak exercise and AT, reduced
O2 pulse, and slowed VO2 kinetics during and following
exercise reﬂect RV dysfunction, reduced CO, and an oxy-
gen deﬁcit during exercise [31, 111]. Oxygen desaturation
reﬂects reduced mixed venous oxygen saturation (along with
reduced O2 uptake in the lungs), further reﬂecting reduced
CO and inadequate O2 delivery [69]. The well-described
elevation in ˙ VE/ ˙ VCO2 [17, 31, 35, 75, 99, 101, 108, 109]
and the relationship between ˙ VE/ ˙ VCO2 and cardiac function
described in PAH suggest that high values of ˙ VE/ ˙ VCO2
reﬂect high levels of RV pressure and workload [75, 101].
LowandfallingPetCO2 atrestandduringexercisereﬂectlow
levelsofPaCO2 [71]associatedwithaventilatorydrivethatis
disconnected from carbon dioxide production. Low PetCO2
is also suggestive of hyperventilation related to elevated RV
pressure and workload.
8. ExerciseAbnormalities andthe Functional
Consequences of Exercise-InducedPAH
Invasive evaluation of central hemodynamics during exercise
identiﬁes individuals who do not meet the diagnostic criteria
for PAH but who have an elevated pulmonary artery
pressure and reduced CO at peak exercise (exercise-induced
PAH (EIPAH)) [112, 113]. These individuals demonstrate
abnormalities during exercise which are characteristic of the
changes seen in PAH, albeit of a milder severity [114]. In
comparison to a healthy control group, individuals with
EIPAH have reduced peak VO2, reduced VO2 at AT [112,
113],reducedO2 pulse(Fowleretal.,unpublished data),and
a tendency towards arterial desaturation [113]. Individuals
with EIPAH also demonstrate elevated ˙ VE/ ˙ VCO2, reduced
PetCO2 at the AT, and an attenuated rise in PetCO2 from rest
to the AT [113]. A higher proportion of these individuals ter-
minate exercise because of dyspnea, compared with matched
healthy controls (41% versus 5%, resp.) [113]. Furthermore,
individuals with EIPAH are in NYHA functional class II or
III and have reduced 6MWD [115]a n dQ o L[ 113] and lower
limb muscle strength compared with healthy individuals
[116]. While it is uncertain whether EIPAH is a progressive
pulmonary vasculopathy similar to PAH, it is apparent that
exercise abnormalities identiﬁed during formal exercise test-
ing reﬂect a similar mechanism of exercise limitation, signs
consistent with impaired RV function during exercise, and
possiblyearlysystemicsequelaeofapulmonaryvasculopathy
(including muscle dysfunction), as described in PAH.
9. The Relationship between
VentilationandDyspnoea
The relationship between ventilation and dyspnea is well
established, from studies of healthy individuals during exer-
cise and in individuals with disease. Aﬀerent neural input
relays details of ventilation from respiratory muscle spindles
to the respiratory centre in the medulla [117]. Ventilation
during rest and light exercise occurs with little or no
awareness of breathing [118]. However, an increase in
motor command to ventilatory muscles is perceived as a
sensation of respiratory work/eﬀort, or dyspnea [78], and
the increase in ventilation required to perform moderate or
intense exercise is accompanied by an increasing awareness
of breathing to a point where breathlessness is described,
even in healthy subjects [118]. An individual with PAH
has a greater ventilatory demand and minute ventilation
throughout submaximal exercise and registers an awareness
of breathing during lower levels of exercise than a healthy
individual [35]. This describes an association between ele-
vated ventilation and dyspnea in PAH.
10. Factors That Contributeto Fatiguein PAH
A sensation of fatigue is commonly reported in LHF, COPD,
and PAH and is described as the limiting factor during exer-
cise testing in up to half of individuals with these conditions
[35, 119]. In LHF, muscle fatigue and early termination
of exercise have been shown to be directly associated with
reduced CO and leg blood ﬂow and increased arterial lactate
concentrations [120]. Through these mechanisms, reduced
CO is considered to inﬂuence the sensation of general fatigue
in individuals with LHF. It has been proposed that slowed
VO2 kinetics and oxygen deﬁcit in individuals with PAH are
associated with similar depletion of high-energy compounds
in the muscle as in LHF [31].
A change in muscle ﬁbre proportion, with a reduction in
t y p eIa n da ni n c r e a s ei nt y p eI Im u s c l eﬁ b r e s[ 93], results in
reduced aerobic capacity, early anaerobic metabolism, and
an increased propensity for fatigue in the muscles in PAH.
Similar changes in muscle morphology and function in LHF
and COPD are believed to be important factors contributing
to the sensation of fatigue during exercise and reduced
exercise capacity, in these conditions [121]. The skeletal
muscle abnormalities identiﬁed in PAH [93] are also likely
to contribute to the sensation of fatigue associated with this
condition.
11. Summary and Conclusions
An acute increase in PAP and RV workload, in association
with reduced oxygen delivery during exercise, and the longer
term systemic and peripheral sequelae of PAH contribute
to increased ventilation during exercise in individuals with
PAH. The sensation of dyspnea reﬂects elevated ventila-
tion during exercise and represents a limited capacity for
increasing CO to meet the elevated metabolic demands of
physical activity. While longer-term sequelae of reduced CO
and tissue oxygenation contribute to fatigue in PAH, in the
shortterm,fatiguesigniﬁesinadequatetissueoxygendelivery
related to an attenuated rise in CO during exercise.
The symptoms of dyspnea and fatigue associated with
PAH reﬂect both acute and chronic RV dysfunction, inﬂu-
ence functional class, and, indirectly, predict survival. The
level of these symptoms on exertion is used by clinicians6 Pulmonary Medicine
to grade disease severity and prognosis in individuals with
PAH. Clinicians are encouraged to also use these symptoms
to guide and monitor the response to physical activities and
exercise training in individuals with PAH. Severe dyspnea
and fatigue are likely to reﬂect high levels of RV work,
which exceed RV capacity, and which potentially contribute
to RV ischemia, inﬂammation and progressive RV failure in
individuals in whom there is active disease progression.
A CPET identiﬁes ﬁndings consistent with RV dysfunc-
tion during exercise in individuals with PAH. A CPET
also identiﬁes a pulmonary vasculopathy and impaired RV
function during exercise in symptomatic individuals who
do not meet the diagnostic criteria for PAH. The CPET is
encouraged as a tool to identify the functional consequences
of PAH, to stratify symptomatic individuals for invasive
evaluation, and for longitudinal followup in individuals who
do not have PAH on initial assessment but who are at
increased risk for developing PAH.
The evidence from exercise training studies, to date, sug-
gests that, at least in the short term, exercise training at
moderate intensity is associated with improved exercise
capacity, without adverse outcomes, in individuals who are
stable on PAH-speciﬁc therapy. For individuals with PAH
who intend to undertake an exercise training program,
wherever possible, a prior CPET is encouraged. A CPET
allows the opportunity to screen individuals for risks asso-
ciated with exercise (e.g., an abnormal blood pressure or
heart rate response) and allows accurate determination of
exercise intensity. The exercise intensity employed during
training should be prescribed according to the individuals’
CPET results, including the maximum heart rate response
(especially in light of chronotropic impairment in PAH) and
symptomatic responses at submaximal and maximal exer-
cise. Clinicians are strongly encouraged to utilize symptoms
to monitor and guide exercise workload and physical activity
levels. Increasing or severe fatigue and/or severe dyspnea
during exercise suggest a high level of RV work, which may
have a detrimental impact on RV function.
12.FutureResearch
While there are data which describe exercise limitation
and provide insights into the likely origin and symptoms
associated with PAH, further research is required to conﬁrm
and expand these ﬁndings. This research might include
studies to clarify the role of central hemodynamics and the
RV in the origin of symptoms and exercise limitation in
this population. Invasive measures of RV function during
exercise are feasible, can be performed without adverse
events and oﬀer insights into the hemodynamic responses
associated with exercise. Evaluation of the role of the central
ventilatorydrive,chronicmuscleacidosis,theergoreﬂex,and
muscle dysfunction (including the role of deconditioning)
would also be of value.
Complementary studies exploring the mechanisms by
which exercise training improves symptoms, exercise capac-
ity, and QoL are also required. Further studies are needed
to determine the optimal intensity for exercise training and
the appropriate level of symptoms during physical activity
for individuals with PAH. These studies should include
randomised controlled trials directed at determining the
longer-term outcomes of exercise training on central hemo-
dynamics, RV function, disease progression, exercise capac-
ity, and QoL. Trial endpoints might include measures of
RV function (ideally using magnetic resonance imaging,
invasive hemodynamics or echocardiography), the asso-
ciation between symptoms and RV function, biomarkers
such as brain natriuretic peptide, QoL, longer-term changes
in physical function and usual activity levels, peripheral
endothelial function, muscle strength, endurance and mor-
phology (according to the exercise modality studied), and
the ventilatory response during submaximal and maximal
exercise testing.
Previous work in animal models of PAH suggests that
exercise training trials in animal models are feasible and
useful. The ﬁndings suggest that studies of exercise training
in animal models may allow exploration of histological con-
sequences of training, and exploration of exercise intensities
that are currently considered potentially unsafe in human
studies. Further exploration of the utility of ventilatory
response during exercise as a surrogate for RV function
would also be of value in animal, and human, studies.
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